Roman Christian Hillig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Roman Christian Hillig has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Korr
Nuvisan ICB GmbH, Berlin, Germany
16 shared publications - Ulf Boemer
Nuvisan ICB GmbH, Muellerstrasse 178, 13353 Berlin, Germany
16 shared publications - Volker Klaus Schulze
Research and Development, Pharmaceuticals, Bayer AG, Muellerstrasse 178, 13353 Berlin, Germany
16 shared publications - Andrew D. Cherniack
Broad Institute of MIT and Harvard, Cambridge, MA, USA
15 shared publications - Bethany Kaplan
Broad Institute of MIT and Harvard 1 Cancer Program Cambridge, Massachusetts
15 shared publications - Daniel Denney
Broad Institute of MIT and Harvard 1 Cancer Program Cambridge, Massachusetts
15 shared publications
Latest Publications
- Open Access
- 27 August 2026
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section D Structural Biology
- Vol. 82 (9) , 1111-1124
KAT6A–inhibitor co-crystal structures: tackling a challenging crystallization target via two alternative approaches
The histone lysine acetyltransferase KAT6A belongs to the MYST family of lysine acetyltransferases which consists of five isoforms. KAT6A (and its paralog KAT6B) have emerged as a promising epigenetic drug targets in cancer, supported by recent clinical data. As support for our high-throughput screening approach aimed at discovering new inhibitors of KAT6A, we developed a crystallization platform system termed KAT6A mutCys in which four surface cysteine residues of KAT6A were mutated to serine. This construct crystallizes readily when in complex with its cofactor AcCoA. The obtained co-crystals were successfully used in a back-soaking approach in which AcCoA was soaked out of the crystals and small-molecule inhibitors were soaked in. In parallel, we explored a previously published surrogate approach termed MYST cryst in which active-site residues of the related, but easier to crystallize, enzyme KAT8 were mutated to those found in KAT6A. By comparing co-crystal structures of the same ligand bound to KAT6A from our Cys-to-Ser approach and to mutated KAT8 (MYST cryst ) we found that the KAT8 surrogate approach indeed successfully reproduced the binding mode observed in the KAT6A structure, while delivering structures with significantly higher resolution. The MYST cryst approach was therefore employed to determine the binding modes of two further small-molecule inhibitors, both from our KAT6A inhibitor optimization program and from a competitor lead series. These structures reveal alternative inhibitor conformations at the binding-site entry and the importance of filling a hydrophobic subpocket in the interior of the binding pocket. These insights will aid future efforts towards the development of KAT6A inhibitors as anticancer drugs.
- 27 August 2026
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section D Structural Biology
- Vol. 82 (9) , 1111-1124
Open AccessKAT6A–inhibitor co-crystal structures: tackling a challenging crystallization target via two alternative approaches
The histone lysine acetyltransferase KAT6A belongs to the MYST family of lysine acetyltransferases which consists of five isoforms. KAT6A (and its paralog KAT6B) have emerged as a promising epigenetic drug targets in cancer, supported by recent clinical data. As support for our high-throughput screening approach aimed at discovering new inhibitors of KAT6A, we developed a crystallization platform system termed KAT6A mutCys in which four surface cysteine residues of KAT6A were mutated to serine. This construct crystallizes readily when in complex with its cofactor AcCoA. The obtained co-crystals were successfully used in a back-soaking approach in which AcCoA was soaked out of the crystals and small-molecule inhibitors were soaked in. In parallel, we explored a previously published surrogate approach termed MYST cryst in which active-site residues of the related, but easier to crystallize, enzyme KAT8 were mutated to those found in KAT6A. By comparing co-crystal structures of the same ligand bound to KAT6A from our Cys-to-Ser approach and to mutated KAT8 (MYST cryst ) we found that the KAT8 surrogate approach indeed successfully reproduced the binding mode observed in the KAT6A structure, while delivering structures with significantly higher resolution. The MYST cryst approach was therefore employed to determine the binding modes of two further small-molecule inhibitors, both from our KAT6A inhibitor optimization program and from a competitor lead series. These structures reveal alternative inhibitor conformations at the binding-site entry and the importance of filling a hydrophobic subpocket in the interior of the binding pocket. These insights will aid future efforts towards the development of KAT6A inhibitors as anticancer drugs.
- Open Access
- 18 May 2026
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section F Structural Biology Communications
- Vol. 82 (6) , 222-230
Structural analysis of the flexibility of the Ubl2 domain within the papain-like protease of SARS-CoV-2
The papain-like protease (PLpro) of SARS-CoV-2 is part of the multi-domain nonstructural protein 3 (NSP3) and consists of two domains: a ubiquitin-like domain 2 (Ubl2) and a protease domain. PLpro plays a crucial role in the replication cycle of SARS-CoV-2, facilitating host immune-system evasion and the formation of double-membrane vesicles where replication occurs. While the function of the Ubl2 domain is still not clear, it is critical for the stability and the functional efficiency of PLpro. Despite its predicted inherent flexibility, nearly all SARS-CoV-1 and SARS-CoV-2 PLpro crystal structures deposited in the Protein Data Bank show the Ubl2 domain in a highly similar, closed conformation against the catalytic domain. Here, we present a crystal structure of PLpro exhibiting Ubl2 in two distinct conformations: the well characterized closed state, where Ubl2 is positioned near the PLpro domain, and an as yet uncharacterized open state, where Ubl2 is displaced by 4 Å from the PLpro core. This conformational variability in our structure appears to be related to the occupancy of a zinc ion within the zinc-finger domain. These results provide new insights into the flexibility of Ubl2, suggesting potential avenues for targeting and harnessing this dynamic behaviour for drug discovery.
- 18 May 2026
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section F Structural Biology Communications
- Vol. 82 (6) , 222-230
Open AccessStructural analysis of the flexibility of the Ubl2 domain within the papain-like protease of SARS-CoV-2
The papain-like protease (PLpro) of SARS-CoV-2 is part of the multi-domain nonstructural protein 3 (NSP3) and consists of two domains: a ubiquitin-like domain 2 (Ubl2) and a protease domain. PLpro plays a crucial role in the replication cycle of SARS-CoV-2, facilitating host immune-system evasion and the formation of double-membrane vesicles where replication occurs. While the function of the Ubl2 domain is still not clear, it is critical for the stability and the functional efficiency of PLpro. Despite its predicted inherent flexibility, nearly all SARS-CoV-1 and SARS-CoV-2 PLpro crystal structures deposited in the Protein Data Bank show the Ubl2 domain in a highly similar, closed conformation against the catalytic domain. Here, we present a crystal structure of PLpro exhibiting Ubl2 in two distinct conformations: the well characterized closed state, where Ubl2 is positioned near the PLpro domain, and an as yet uncharacterized open state, where Ubl2 is displaced by 4 Å from the PLpro core. This conformational variability in our structure appears to be related to the occupancy of a zinc ion within the zinc-finger domain. These results provide new insights into the flexibility of Ubl2, suggesting potential avenues for targeting and harnessing this dynamic behaviour for drug discovery.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Antiproliferative activity of sevabertinib and EGFR/HER2 tyrosine kinase inhibitors in Ba/F3 cell lines with HER2 Exon 20 insertion mutations
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Antiproliferative activity of sevabertinib and EGFR/HER2 tyrosine kinase inhibitors in Ba/F3 cell lines with HER2 Exon 20 insertion mutations
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
The binding mode of sevabertinib within the ATP binding site of wild-type EGFR from two different views
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
The binding mode of sevabertinib within the ATP binding site of wild-type EGFR from two different views
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Antitumor efficacy of sevabertinib in the subcutaneous CTG-2543 xenografts
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Antitumor efficacy of sevabertinib in the subcutaneous CTG-2543 xenografts
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Sevabertinib response and sensitivity to ERBB family gene CRISPR knockout or RNAi knockdown
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Sevabertinib response and sensitivity to ERBB family gene CRISPR knockout or RNAi knockdown
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Biochemical kinase activity of sevabertinib in ERBB and non-ERBB family kinases
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Biochemical kinase activity of sevabertinib in ERBB and non-ERBB family kinases
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
NRG1 fusions in cancer cell lines
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
NRG1 fusions in cancer cell lines
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Sevabertinib inhibition in KinaseProfiler kinase activity platform
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Sevabertinib inhibition in KinaseProfiler kinase activity platform
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Supplementary Methods: Crystal Structure Determination of Wild-Type EGFR in Complex with Sevabertinib. Xenograft models
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Supplementary Methods: Crystal Structure Determination of Wild-Type EGFR in Complex with Sevabertinib. Xenograft models